Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations

Human papillomavirus (HPV), a non-enveloped, double-strand DNA viral pathogen, is intricately linked with the onset of various cancers, including cervical cancer and head and neck cancers. The present paper delves into HPV's ancient recognition and significant milestones such as the discovery of its role in oncogenesis and the development of preventive vaccines all the way to routine treatments and newer, cutting-edge interventions. It highlights therapeutic advancements, including immunotherapies, gene-editing technologies, and emerging vaccination strategies as well as the personalized HPV-treatments plans to treat established infections. Challenges, such as vaccine accessibility, therapeutic resistance, and immune evasion, are examined, trying to capture the stigma around HPV and the social complications relating to the disease. The review concludes with future directions emphasizing innovation, equity in treatment access, and the integration of novel therapies to eradicate HPV-associated diseases and highlight the necessity of Global eradication going forward. This paper aims to traverse the historical origins, molecular pathways, and clinical interventions aimed at understanding and managing HPV.